finance.yahoo.com ·
Legend Biotech Legn Gets Bullish
Topic context
This topic has been covered 249707 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article covers Legend Biotech, a CAR-T therapy developer. The stock surge is driven by analyst upgrades and positive sector sentiment following Eli Lilly's acquisition of Kelonia. The commercial mechanism is weak: no direct revenue or cost impact beyond general market optimism. The company's revenue growth is strong but losses are widening. No concrete supply chain or scarcity effects are identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Legend Biotech stock rose 18.42% to $25.07 after bullish analyst coverage.
- RBC Capital maintained outperform with $62 price target; HC Wainwright reiterated buy with $50 target.
- Eli Lilly acquired Kelonia for $3.25 billion, boosting CAR-T therapy market sentiment.
- Legend Biotech 2024 total revenues rose 64% to $1.029 billion; net loss widened 68% to $296.8 million.
- Key in vivo CD19/CD20 CAR-T data expected at 2026 ASCO Annual Meeting.
Mid-term outlook for CAR-T therapies is down; widening losses could pressure cash runway and equity dilution.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
Related stories
finance.yahoo.com
Manulife Financial Q1 Earnings Call
finance.yahoo.com
Nextera Dominion Energy Merger Create
finance.yahoo.com
Ascend Wellness Q1 Earnings Call
finance.yahoo.com
Eurodry Edry Q1 2026 Earnings
moneycontrol.com